# Zhejing Meihua Dingchang Pharmaceutical Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/zhejing-meihua-dingchang-pharmaceutical-co

- Industry: Biotechnology
- Headquarters: Shaoxing, China
- Website: www.mhdcpharma.com
- Total disclosed funding: $15M
- Latest round: Series B (Jul 5, 2021)
- Investors on record: 3

## About

Established in 2011 and based in Shaoxing, China, Zhejing Meihua Dingchang Pharmaceutical Co. Ltd. is a biomedical company that focuses on product development of new drugs and generic new drugs. The chairman and general manager Dr. Chuanyue Wang graduated from the University of Ghent, Belgium with a PhD. She worked in Wyeth Pharmaceuticals Global Analysis and Development Center and Teva Pharmaceuticals in drug research. In July 2021, the company raised series B funding from new investor.

The company provides generic new drug formulations research and development, cGMP (current good manufacture practices) quality standard control, innovative drug development, analytical testing, and project approval to FDA services for biopharmaceutical industry. The company's main self-developed products include oral controlled-release, bio-peptide and essential oil tablets and so on.

The company plans to use the fund of series B funding to promote the construction of GMP (good manufacture practices) production line for innovative microsphere long-acting injections.

## Funding rounds

- Series B, Jul 5, 2021, $15M — TTGG Ventures, Liyuan Venture Capital, Shulan Junjie Capital

## Investors

- TTGG Ventures (https://capitalatlas.ai/funds/ttgg-ventures) — Series B
- Liyuan Venture Capital (https://capitalatlas.ai/funds/liyuan-venture-capital) — Series B
- Shulan Junjie Capital (https://capitalatlas.ai/funds/shulan-junjie-capital) — Series B